- The head of the vaccine trials in the UK has made plain that she does not expect a sterilising vaccine - only one that approaches 50% efficacy.
- Andrew Pollard (Head of the Oxford Vaccine Trial Team) said:-
'Until we've got a high level of immunity in the population so that we can stop the virus so most vulnerable people are immune, there is going to be a risk. Initially, we're going to be in a position where mask-wearing and social distancing don't change.
'Only when there is a big drop in serious cases will governments feel able to relax these measures. This is a very easily transmissible virus.'
The logical conclusion to be drawn from these statements is that the present restrictions are going to continue well beyond next summer if the vaccine is not sterilising (which appears to be likely).
As I keep saying, if 50,000 covid deaths are unacceptable this year, why would 25,000 be ok next year?
There is also an important subsidiary point which no one is talking about: hospital capacity in the future. The NHS can barely cope with a normal flu season. It will cope this winter because we are likely to be locked down and lots of other health care has been postponed.
How will it cope next year with normal flu and 50% covid deaths without restrictions being imposed.
We might have more treatments next year and the vaccine may be better than we accept. Also, excess mortality may not readily distinguish between flu and covid and they may take the same lives.
However, all things considered, there is a slightly ominous feeling about there being no return to "normal" in the spring.